Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
AssigneeGuilford Pharmaceuticals Inc.
InventorGregory S. Hamilton
Life of this patent
Estimating the term…
Abstract
The present invention pertains to antagonists of excitatory amino acid receptors, their method of preparation as well as compositions pertaining to them, which have the general formula: ##STR1## wherein n is 0, 1, 2, or 3; R1 and R.sub.2 are selected from the group consisting of hydrogen, halogen, halomethyl, nitro, amino, alkoxy, hydroxyl, hydroxymethyl, C.sub.1 to C.sub.6 lower alkyl and C.sub.7 to C.sub.12 higher alkyl, aryl and aralkyl; and the pharmaceutically acceptable salts thereof.
Claims6
A method for treating a mammal in need thereof with an excitatory amino acid inhibitory compound, comprising the step of administering an effective amount of the following compound:
- ##STR15## wherein n is 1, 2 or 3 ;
- R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, halogen, halomethyl, nitro, amino alkoxy, hydroxyl, hydroxymethyl, C.sub.1 to C.sub.6 lower alkyl and C.sub.7 to C.sub.12 higher alkyl, aryl and aralkyl, or the pharmaceutically acceptable salts thereof, except R.sub.1 and R.sub.2 are not nitro and chloro when n is 1.
A pharmaceutical composition for relieving pain and treating convulsions, cerebral ischemic damage, and emesis, which comprises:
- an effective amount of a compound having the formula:
- ##STR16## wherein n is 1, 2 or 3;
- R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, halogen, halomethyl, nitro, amino alkoxy, hydroxyl, hydroxymethyl, C.sub.1 to C.sub.6 lower alkyl and C.sub.7 to C.sub.12 higher alkyl, aryl and aralkyl, or the pharmaceutically acceptable salts thereof, except R.sub.1 and R.sub.2 not nitro and chloro when n is 1;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.